Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed, Inc. (Symbol: INSM) is a global biopharmaceutical company headquartered in Bridgewater, NJ, with a mission to transform the lives of patients with serious and rare diseases. The company is committed to developing and bringing to market therapies that significantly improve patient lives, focusing on the entire patient journey from diagnosis and treatment to daily living.
Insmed's flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the US for treating Mycobacterium Avium Complex (MAC) lung disease in adult patients who have limited or no alternative treatment options. ARIKAYCE, utilizing Insmed's proprietary PULMOVANCE® liposomal technology, delivers amikacin directly to the lungs, reducing systemic exposure and associated toxicities. It is administered using the Lamira® Nebulizer System developed by PARI Pharma GmbH, known for its efficiency and portability.
The company’s clinical pipeline includes multiple promising candidates. Notable among them is Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is being developed for treating non-cystic fibrosis bronchiectasis and other neutrophil-mediated diseases. Another significant pipeline product is TPIP (Treprostinil Palmitil Inhalation Powder), an inhaled formulation being evaluated for pulmonary arterial hypertension and other serious pulmonary disorders.
Insmed has demonstrated robust financial performance, with significant revenue growth driven by ARIKAYCE. The company continues to invest heavily in research and development, with plans to expand its product portfolio and market reach globally.
Insmed's strategic partnerships and collaborations play a crucial role in advancing its mission. These include collaborations with PARI Pharma for the Lamira® Nebulizer System and AstraZeneca AB for utilizing their expertise in respiratory diseases.
Recent updates include positive financial results for the third quarter of 2023, robust revenue growth from ARIKAYCE, and significant progress in clinical trials. Noteworthy are the topline results from the Phase 3 ASPEN study for Brensocatib, indicating its potential as a first-in-class treatment. Insmed plans to file a New Drug Application (NDA) with the FDA for Brensocatib by late 2024, aiming for a potential launch in 2025.
The company is also advancing its early-stage research engine, exploring innovative technologies such as artificial intelligence-driven protein engineering and gene therapy, positioning itself at the forefront of biopharmaceutical innovation.
Insmed has priced a public offering of 10 million shares at $25 each, raising $250 million, alongside a $500 million offering of 0.75% convertible senior notes due 2028. A portion of the notes proceeds will repurchase $225 million of existing convertible notes due 2025. The offerings, set to close by May 13, 2021, are expected to bolster Insmed's funds for commercialization and development of ARIKAYCE and other products. The convertible notes feature a conversion price of approximately $32.50 per share, with a contingent option for underwriters to purchase additional shares and notes.
Insmed Incorporated (Nasdaq: INSM) plans to offer $250 million of common stock and $500 million in convertible senior notes due 2028. Proceeds will partially fund the repurchase of existing convertible senior notes due 2025 and support the commercialization of ARIKAYCE and development of other product candidates. The offerings include options for underwriters to purchase an additional 15% of shares and notes. The offerings are subject to market conditions and may not be completed as planned.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to nine new employees as part of their employment agreements, in line with NASDAQ Listing Rule 5635(c)(4). The awards, approved by the Compensation Committee, consist of options to purchase 49,410 shares of common stock at an exercise price of $32.94 per share, the closing price on May 3, 2021. These options will have a ten-year term with a four-year vesting schedule. Insmed focuses on developing therapies for serious and rare diseases, including chronic lung conditions.
Insmed reported its Q1 2021 financial results, highlighting total revenue of $40.2 million, up from $36.9 million in Q1 2020. The net loss increased to $91.6 million or $0.89 per share, compared to $66.4 million or $0.74 per share a year earlier. ARIKAYCE was approved in Japan, expanding its market presence, and patient enrollment for ongoing clinical studies continues. The company maintains a cash position of $409.8 million and plans significant investments in clinical and commercialization activities throughout 2021.
Insmed Incorporated (Nasdaq: INSM) has announced the release date for its first quarter 2021 financial results as May 6, 2021. A conference call for investors will take place at 8:30 a.m. ET on the same day, where management will discuss the financial outcomes and provide a business update. Interested parties can join the call through a provided dial-in number or via a live webcast on the company's website. The company focuses on transforming the lives of patients with serious and rare diseases, having a first-in-disease therapy approved in the US, Europe, and Japan.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to eight new employees, as per NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, the awards included options for 247,850 shares at an exercise price of $35.44 per share. The options have a ten-year term with a four-year vesting schedule. Notably, two employees received additional performance-based options tied to regulatory milestones. Insmed aims to support its mission to transform lives of patients with rare diseases and has a pipeline of investigational therapies.
Insmed Incorporated (Nasdaq: INSM) announces MHLW approval for ARIKAYCE® in Japan to treat nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC) for patients unresponsive to previous multidrug therapies. This launch, expected in mid-2021, marks a significant advancement for patients facing this serious disease, currently lacking approved treatment options. The approval is based on positive results from the Phase 3 CONVERT study, showing improved sputum culture conversion rates with ARIKAYCE combined with MDR. An associated patient support program will also be introduced.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to seven new employees to enhance recruitment efforts. On March 1, 2021, these employees received options to purchase 27,770 shares of common stock at $37.73 per share, based on the Nasdaq closing price. This follows a previous grant on February 5, 2021, where options for 65,980 shares were incorrectly reported and later corrected to 60,020 shares at an exercise price of $37.44. The awards align with NASDAQ Listing Rule 5635(c)(4).
Insmed Incorporated (Nasdaq: INSM) reported Q4 and full-year 2020 financial results, demonstrating significant growth. Total revenue for Q4 was $41.4 million, down from $45.7 million in Q4 2019, while full-year revenue rose to $164.4 million, up from $136.5 million in 2019. GAAP net loss for Q4 increased to $102.2 million ($1.00 per share) compared to a $53 million loss in Q4 2019. R&D expenses surged to $67.8 million in Q4 2020. Insmed continues advancing ARIKAYCE and brensocatib with promising trials, anticipating a strong 2021 with cash reserves of $532.8 million.
Insmed announces participation in two virtual investor conferences. The company will present at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 11:40 a.m. ET, and at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET. Webcasts of both events will be available on Insmed's investor relations website and archived for 30 days. Insmed focuses on developing therapies for serious and rare diseases, with its first commercial product approved for a chronic lung disease.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
What is Insmed's primary mission?
What is ARIKAYCE?
What are Brensocatib and TPIP?
Where is Insmed headquartered?
What are Insmed's recent financial highlights?
What are the strategic partnerships of Insmed?
What are the latest developments in Insmed's clinical trials?
What is Insmed's approach to early-stage research?
What is the Lamira® Nebulizer System?
When does Insmed plan to file an NDA for Brensocatib?
